CopyMark Law Group
4.9
Drawing for INBRACE SUPPORT PROGRAM

USPTO serial 90123459

INBRACE SUPPORT PROGRAM

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NIEMANN, SHELBY LYNN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with INBRACE SUPPORT PROGRAM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Goods and services

ClassDescriptionStatusFirst use
035Promoting the interests of people who have Parkinson's disease and their families and health care providers by means of public advocacy; promoting the interests of people who have Friedreich's ataxia and their families and health care providers by means of public advocacy; promoting the interests of people who have congenital birth defects and their families and health care providers by means of public advocacy; promoting the interests of people who have rare pediatric epilepsies and their families and health care providers by means of public advocacy; promoting the interests of people who have SCN8A developmental and epileptic encephalopathy and their families and health care providers by means of public advocacy; promoting the interests of people who have congenital adrenal hyperplasia and their families and health care providers by means of public advocacy; promoting the interests of people who have neurological diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have central nervous system diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have psychiatric diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have movement diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have endocrine diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have hormonal diseases and their families and health care providers by means of public advocacy; promoting the interests of people who have genetic diseases and their families and health care providers by means of public advocacyACTIVE—
042Creating an online community for people who have Parkinson's disease and their families and health care providers for the purpose of engaging with and sharing information in the field of Parkinson's disease; creating an online community for people who have Friedreich's ataxia and their families and health care providers for the purpose of engaging with and sharing information in the field of Friedreich's ataxia; creating an online community for people who have congenital birth defects and their families and health care providers for the purpose of engaging with and sharing information in the field of congenital birth defects; creating an online community for people who have rare pediatric epilepsies and their families and health care providers for the purpose of engaging with and sharing information in the field of rare pediatric epilepsies; creating an online community for people who have SCN8A developmental and epileptic encephalopathy and their families and health care providers for the purpose of engaging with and sharing information in the field of SCN8A developmental and epileptic encephalopathy; creating an online community for people who have congenital adrenal hyperplasia and their families and health care providers for the purpose of engaging with and sharing information in the field of congenital adrenal hyperplasia; creating an online community for people who have neurological diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of neurological diseases; creating an online community for people who have central nervous system diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of central nervous system diseases; creating an online community for people who have psychiatric diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of psychiatric diseases; creating an online community for people who have movement diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of movement diseases; creating an online community for people who have endocrine diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of endocrine diseases; creating an online community for people who have hormonal diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of hormonal diseases; creating an online community people who have genetic diseases and their families and health care providers for the purpose of engaging with and sharing information in the field of genetic diseasesACTIVE—
044Providing medical information regarding pharmaceutical products and services; pharmaceutical consultation, namely, treatment support programs that coordinate insurance, drug delivery and prescription management between physicians, patients, and pharmacies; providing medical and health information in the field of Parkinson's disease; providing medical and health information in the field of Friedreich's ataxia; providing medical and health information in the field of congenital birth defects; providing medical and health information in the field of rare pediatric epilepsies; providing medical and health information in the field of SCN8A developmental and epileptic encephalopathy; providing medical and health information in the field of congenital adrenal hyperplasia; providing medical and health information in the field of neurological diseases; providing medical and health information in the field of central nervous system diseases; providing medical and health information in the field of psychiatric diseases; providing medical and health information in the field of movement diseases; providing medical and health information in the field of endocrine diseases; providing medical and health information in the field of hormonal diseases; providing medical and health information in the field of genetic diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 25, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 25, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 21, 2021NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 27, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 27, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 7, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 22, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 22, 2021XAECEXAMINER'S AMENDMENT ENTERED—
Jun 22, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 22, 2021GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 22, 2021CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 22, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 21, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 21, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 21, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 21, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 15, 2020DOCKASSIGNED TO EXAMINER—
Sep 22, 2020MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Sep 21, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 22, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance